SCHEMBL177422

SCHEMBL177422

Cc1cccc(CBr)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.38
ACHE P22303 2/20 0.37
TAAR1 Q96RJ0 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2A6 P11509 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TSHR P16473 3/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
TRPA1 O75762 1/20 0.33
KIF11 P52732 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
P2RX7 Q99572 1/20 0.32
ELANE P08246 1/20 0.32
SCN4A P35499 2/20 0.31
MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL960397 0.83 GABRA1 (0.36) TAAR1GABRA1GABRB2ALDH1A1TSHR
SCHEMBL10830835 0.83 TAAR1 (0.38) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL489837 0.81 P2RX7 (0.36) P2RX7
SCHEMBL6405866 0.79 TAAR1 (0.46) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL13180051 0.79 MPO (0.39) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL170934 0.79 GABRA1 (0.46) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL13197070 0.78 GABRA1 (0.52) MPOACHETAAR1CYP1A2GABRA1
SCHEMBL1145716 0.77 PDCD1 (0.44) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL8343195 0.77 MPO (0.38) MPOACHETAAR1CYP1A2CYP2A6
SCHEMBL172634 0.77 MPO (0.38) MPOACHETAAR1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698524-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS Alceptor Therapeutics, Inc. (US) 2026-02-25 EP disclosed
US-20260042769-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS ALCEPTOR THERAPEUTICS INC (US) 2026-02-12 US disclosed
US-20260007672-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2026-01-08 US disclosed
US-12491185-B2 Inhibitors of mPTP NRG THERAPEUTICS LTD (GB) 2025-12-09 US disclosed
EP-4652162-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 EP disclosed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-20250177397-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
EP-4561561-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Septerna, Inc. (US) 2025-06-04 EP disclosed
WO-2024220941-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS ALCEPTOR THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed
CN-1202152-A Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency HOFFMANN LA ROCHE (CH) 1998-12-16 CN disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 EP disclosed
US-5756505-A N-acylpiperazine derivative, antibacterial drug and anti-ulcer drug SHISEIDO CO., LTD. (JP) 1998-05-26 US disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed
EP-0735031-A1 N-acetylpiperazine derivative, antibacterial drug, and anti-ulcer drug SHISEIDO COMPANY LIMITED (JP) 1996-10-02 EP disclosed
US-5409943-A [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1995-04-25 US disclosed
EP-0625143-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1994-11-23 EP disclosed
WO-1993015055-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1993-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12491185-B2 Inhibitors of mPTP PARK7, PINK1, SNCA MPO 501/4885ACHE 235/4885TAAR1 728/4885
US-20250177397-A1 INHIBITORS OF MPTP PARK7, PINK1, SNCA MPO 501/4885ACHE 235/4885TAAR1 728/4885
US-20260042769-A1 TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS ADRB2, ADRB1, ADRB3 MPO 3092/4885ACHE 1384/4885TAAR1 115/4885
US-20260007672-A1 INHIBITORS OF MPTP PARK7, SNCA, CYC1 MPO 1491/4885ACHE 1481/4885TAAR1 195/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 MPO 68/4885ACHE 2785/4885TAAR1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.